Back Back
Cell No. : Cell Name
RCB1151 : RCC10RGB  update : 2022/12/15
CommentKidney carcinoma from a Japanese patient.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (
Basic information Depositor Ohno, Tadao
Originator Hashizaki, K.
Year of deposit 1995
Another name Hpt.10
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Tissue kidney
Classification cancer
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_1647
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/3-4 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP
Chromosome mode 73-80(50) : /75(11), 76(8), 77(8), 78(11), 79(3)/
STR(human) OK
deposit info
lot info
Reference information Reference 0
User's Publication 14

To topTop

To topTop
User's Publication
20629  Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.  Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.  Proc Natl Acad Sci U S A  2022  119(14):e2120403119  PubMed ID: 35357972   DOI: 10.1073/pnas.2120403119
16366  Emberley E, Pan A, Chen J, Dang R, Gross M, Huang T, Li W, MacKinnon A, Singh D, Sotirovska N, Steggerda SM, Wang T, Parlati F.  The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma  PLoS One  2021  16(11):e0259241  PubMed ID: 34731180   DOI: 10.1371/journal.pone.0259241
3749  Zou Y, Palte MJ, Deik AA, Li H, Eaton JK, Wang W, Tseng YY, Deasy R, Kost-Alimova M, Dančík V, Leshchiner ES, Viswanathan VS, Signoretti S, Choueiri TK, Boehm JS, Wagner BK, Doench JG, Clish CB, Clemons PA, Schreiber SL.  A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis.  Nat Commun  2019  10(1):1617  PubMed ID: 30962421   DOI: 10.1038/s41467-019-09277-9
10839  Tsuchida A, Senda M, Ito A, Saito S, Kiso M, Ando T, Harduin-Lepers A, Matsuda A, Furukawa K, Furukawa K.  Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells.  Sci Rep  2018  8:7017  PubMed ID: 29728594   DOI: 10.1038/s41598-018-25521-6
3740  Sinha R, Winer AG, Chevinsky M, Jakubowski C, Chen YB, Dong Y, Tickoo SK, Reuter VE, Russo P, Coleman JA, Sander C, Hsieh JJ, Hakimi AA.  Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.  Nat Commun. 2  2017  8:15165  PubMed ID: 28489074   DOI: 10.1038/ncomms15165
8356  Hosono T, Tanaka T, Tanji K, Nakatani T, Kamitani T.  NUB1, an interferon-inducible protein, mediates anti-proliferative actions and apoptosis in renal cell carcinoma cells through cell-cycle regulation.  Br. J. Cancer  2010  102:873-82  PubMed ID: 20160729   DOI: 10.1038/sj.bjc.6605574
6387  Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, Okada Y, Okamoto K.  DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma.  Clin Cancer Res  2010  16(10):2751-9  PubMed ID: 20460473   DOI: 10.1158/1078-0432.CCR-09-3338
6393  Inowa T, Hishikawa K, Matsuzaki Y, Isagawa T, Takeuchi T, Aburatani H, Kitamura T, Fujita T.  GADD45β Determines Chemoresistance and Invasive Growth of Side Population Cells of Human Embryonic Carcinoma.  Stem Cells Int  2010  2010:782967  PubMed ID: 21048853   DOI: 10.4061/2010/782967
3719  van Haaften G et al  Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer.  Nat Genet  2009  41(5):521-3  PubMed ID: 19330029   DOI: 10.1038/ng.349
8851  Domoto T, Miyama Y, Suzuki H, Teratani T, Arai K, Sugiyama T, Takayama T, Mugiya S, Ozono S, Nozawa R.  Evaluation of S100A10, annexin II and B-FABP expression as markers for renal cell carcinoma.  Cancer Sci.  2007  98:77-82  PubMed ID: 17083565   DOI: 10.1111/j.1349-7006.2006.00355.x
3396  Yamada, Daisuke, Kikuchi, Shinji, Williams, Yuko N, Sakurai-Yageta, Mika, Masuda, Mari, Maruyama, Tomoko, Tomita, Kyoichi, Gutmann, David H, Kakizoe, Tadao, Kitamura, Tadaichi, Kanai, Yae, Murakami, Yoshinori  Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.  Int J Cancer  2006  118:916-23  PubMed ID: 16152585   DOI: 10.1002/ijc.21450
5012  Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.  Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.  Hum Mol Genet  2006  15(6):821-30  PubMed ID: 16439445   DOI: 10.1093/hmg/ddl001
2661  Kasuya, Yutaka, Hosaka, Yoshio, Matsushima, Hisashi, Goto, Toshitaka, Kitamura, Tadaichi, Okuyama, Akira  Prominent induction of cyclin B1 in G2/M renal cancer cells with butyrolactone 1.  Int J Urol  2003  10:323-31  PubMed ID: 12757604   DOI: 10.1046/j.1442-2042.2003.00626.x
2561  Kasuya Y, Hosaka Y, Matsushima H, Goto T, Kitamura T  Differences in cell kinetic changes among renal cancer cell lines treated with interferon-alpha.  Int J Urol  2001  8:449-54  PubMed ID: 11555012   DOI: 10.1046/j.1442-2042.2001.00346.x

Back Back Return Top Page